- Home
- OPY vs ANAB Comparison
OPY vs ANAB Comparison
Compare OPY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- ANAB
- Stock Information
- Founded
- OPY 1881
- ANAB 2005
- Country
- OPY United States
- ANAB United States
- Employees
- OPY N/A
- ANAB N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- OPY Finance
- ANAB Health Care
- Exchange
- OPY Nasdaq
- ANAB Nasdaq
- Market Cap
- OPY 820.6M
- ANAB 659.6M
- IPO Year
- OPY N/A
- ANAB 2017
- Fundamental
- Price
- OPY $70.48
- ANAB $29.87
- Analyst Decision
- OPY
- ANAB Buy
- Analyst Count
- OPY 0
- ANAB 10
- Target Price
- OPY N/A
- ANAB $50.63
- AVG Volume (30 Days)
- OPY 52.0K
- ANAB 737.6K
- Earning Date
- OPY 10-24-2025
- ANAB 11-04-2025
- Dividend Yield
- OPY 1.00%
- ANAB N/A
- EPS Growth
- OPY 41.03
- ANAB N/A
- EPS
- OPY 7.71
- ANAB N/A
- Revenue
- OPY $1,400,370,000.00
- ANAB $123,164,000.00
- Revenue This Year
- OPY N/A
- ANAB $11.40
- Revenue Next Year
- OPY N/A
- ANAB $8.17
- P/E Ratio
- OPY $9.32
- ANAB N/A
- Revenue Growth
- OPY 14.40
- ANAB 304.17
- 52 Week Low
- OPY $47.39
- ANAB $12.21
- 52 Week High
- OPY $79.99
- ANAB $36.54
- Technical
- Relative Strength Index (RSI)
- OPY 39.65
- ANAB 69.32
- Support Level
- OPY $69.91
- ANAB $30.00
- Resistance Level
- OPY $72.70
- ANAB $32.24
- Average True Range (ATR)
- OPY 1.85
- ANAB 2.08
- MACD
- OPY -0.86
- ANAB 0.91
- Stochastic Oscillator
- OPY 6.40
- ANAB 74.83
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).